Income Statement (TTM)
GlobeStar Therapeutics Corporation Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
|
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Change (%) | -100.00 | NaN | NaN | |
| % of Revenue | 100.00 | |||
| Cost Of Sales | 0 | 0 | 0 | 0 |
| Change (%) | -0.04 | 6.40 | 0.00 | |
| % of Revenue | 48,937.66 | |||
| Gross Operating Profit | -0 | -0 | -0 | -0 |
| Change (%) | 0.17 | 6.40 | -0.00 | |
| % of Revenue | -48,837.66 | |||
| SG&A | 0 | 0 | 1 | 5 |
| Change (%) | -5.24 | 165.24 | 662.39 | |
| % of Revenue | 345,540.26 | |||
| R&D | ||||
| Change (%) | ||||
| % of Revenue | ||||
| OpEx | 0 | 0 | 1 | 5 |
| Change (%) | -4.59 | 144.59 | 624.93 | |
| % of Revenue | 394,477.92 | |||
| Operating Income | -0 | -0 | -1 | -5 |
| Change (%) | -4.57 | 144.59 | 624.93 | |
| % of Revenue | -394,377.92 | |||
| Interest Expense | -0 | -0 | -0 | -0 |
| Change (%) | -9.56 | 21.71 | -1.71 | |
| % of Revenue | -309,168.83 | |||
| Net Income | -1 | -1 | -1 | -6 |
| Change (%) | -6.76 | 153.94 | 345.43 | |
| % of Revenue | -703,546.75 | |||
Source: Capital IQ
